Since the AD diagnosis in the SNAC-N cohort was based on clinical assessment, we next measured the levels of pTau217 and GFAP in blood to assess if individuals with low N-glycosylation also showed evidence of biological AD pathology and neuroinflammation. The gene discussed is GFAP; the disease is Alzheimer disease.